The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex and its industry partners to present at the ASN Kidney Week 2018, October the 27th, 2018, San Diego, CA, USA.

News detail

Return to all news & events

10/26/2018 Physiogenex and its industry partners to present at the ASN Kidney Week 2018, October the 27th, 2018, San Diego, CA, USA.

Physiogenex will be presenting its innovative animal models of diabetic nephropathy, namely the db/db mouse on high protein diet and the Unx/salt supplemented SDT fatty rat, at the ASN Kidney Week 2018, in San Diego, California.

The studies, performed by Physiogenex and industry partners Novo Nordisk, Scohia Pharma and CLEA Japan Inc., will be presented by Dr. François Briand, Director of Research and Business Development at Physiogenex, during the Diabetic Kidney Disease: Basic – III poster session, on Saturday, October the 27h, 10:00 AM – 12:00 PM (posters #SA-PO112 and PO-113)

CLEA representatives, including Dr. Shinohara, the expert who established the SDT fatty rat model, will be also on site to provide information about the model during the conference.

If you wish to know more about our models of Diabetic Nephropathy for setting-up a drug evaluation, ask Physiogenex experts:

If you wish to know more about the SDT fatty rat model for obesity/type 2 diabetes, contact CLEA Japan Inc.:

About CLEA Japan, Inc.

CLEA Japan, Inc. is the expert supplier of experimental rodents, constantly providing best quality bioservices to researchers. Based on its experience acknowledged by pharmaceutical companies, CLEA Japan, Inc. will efficiently provide CRO services with Physiogenex.

Find out more about CLEA Japan, Inc. and the services offered at

About Physiogenex

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.

Please visit our website for more information: